Safety and Efficacy of Emixustat in Stargardt Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

June 13, 2022

Study Completion Date

June 23, 2022

Conditions
Stargardt Disease
Interventions
DRUG

Emixustat

Once daily oral tablet taken for 24 months

DRUG

Placebo

Once daily oral tablet taken for 24 months

Trial Locations (29)

6500

Radboud University Medical Center, Nijmegen

20132

IRCCS Ospedale San Raffaele, Milan

20157

UOC Oculistica Asst Fatebene Pratelli Sacco Universita delgi Studi di Milano, Milan

21287

The Wilmer Eye Institute Johns Hopkins University, Baltimore

27710

Duke Eye Center, Durham

28040

Fundacion Jimenez Diaz University Hospital, Madrid

30322

Emory University, Atlanta

48105

University of Michigan Kellogg Eye Center, Ann Arbor

50134

SODC di Oculistica AOU Careggi, Florence

53127

Universitäts-Augenklinik Bonn, Bonn

53226

Medical College of Wisconsin-Eye Institute, Milwaukee

55905

Mayo Clinic Rochester, Rochester

72076

Universitätsklinikum Tübingen, Department für Augenheilkunde, Tübingen

75012

CHNO Quinze-Vingts - CIC, Paris

75231

Retina Foundation of the Southwest, Dallas

80131

AOU Università della Campania Luigi Vanvitelli, Naples

84132

University of Utah John Moran Eye Center, Salt Lake City

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

94000

Service D'Ophtalmologie Chi Creteil, Créteil

97239

Casey Eye Institute - OHSU, Portland

94143-0730

UCSF Dept. of Ophthalmology, San Francisco

30150-320

Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte

04024-002

Hospital Sao Paulo, São Paulo

MSG 1X8

The Hospital for Sick Children, Toronto

DK-2600

Rigshospitalet-Glostrup, Glostrup Municipality

00168

Università Cattolica del Sacro Cuore - Fondazione Policlinico Gemelli, Rome

0082

Pretoria Eye Institute, Pretoria

OXD3 9DU

Oxford Eye Hospital,Oxford University Hospitals NHS Foundation Trust, Oxford

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

Kubota Vision Inc.

INDUSTRY

NCT03772665 - Safety and Efficacy of Emixustat in Stargardt Disease | Biotech Hunter | Biotech Hunter